Are you or someone you know suffering from Hashimoto’s Thyroiditis? We have groundbreaking news for you! Our new clinical trial is now accepting patients just like you.
About the Study:
This IRB-supported study aims to determine if our early promising results can be consistently reproduced. Our focus is on reducing or eliminating the production of anti-Thyroglobulin Antibodies, a primary culprit in Hashimoto’s Thyroiditis.
Treatment Details:
- Daily (Monday to Friday) comprehensive treatments and supportive therapies.
- One-to-two-week program of care, with virtual follow-up appointments.
- Customized primary treatment utilizing induced native phage therapy, a non-toxic and non-allergenic approach.
Goal:
We aim to stop the body from producing harmful antibodies that attack thyroid hormones, paving the way for symptom relief and improved quality of life.
Prerequisites:
Recent laboratory test results showing high anti-Thyroglobulin Antibodies or anti-Thyroid Peroxidase Antibodies, and a commitment to retesting post-treatment.